de Thé H, Dejean A
Unité de Recombinaison et Expression Génétique (INSERM U163), Institut Pasteur, Paris.
Cancer Surv. 1992;14:195-203.
Acute promyelocytic leukaemia has two highly specific particularities: a t(15;17) chromosomal translocation and the ability of a differentiation inducer all-trans-RA, to revert the malignant phenotype both in vitro and in vivo. Molecular characterization of the t(15;17) translocation has shown that it fuses a previously unknown zinc finger encoding gene, PML, to the RAR alpha, suggesting a link between the molecular mechanism of transformation and of RA dependent differentiation. The PML/RAR alpha fusion receptor--which is functionally altered--may block RA target genes, impair RA mediated differentiation and lead to transformation. Alternatively, or in addition, the PML transduction pathway may also be affected. Although it is clear that RA treatment must relieve APL cells from differentiation arrest, so far no model can satisfactorily account for this effect.
t(15;17)染色体易位以及分化诱导剂全反式维甲酸在体外和体内使恶性表型逆转的能力。t(15;17)易位的分子特征表明,它将一个先前未知的锌指编码基因PML与维甲酸受体α(RARα)融合,提示转化的分子机制与维甲酸依赖性分化之间存在联系。功能改变的PML/RARα融合受体可能会阻断维甲酸靶基因,损害维甲酸介导的分化并导致转化。另外,或者除此之外,PML转导途径也可能受到影响。虽然很明显维甲酸治疗必须使急性早幼粒细胞白血病细胞从分化停滞中解脱出来,但到目前为止,尚无模型能够令人满意地解释这种效应。